Maxwell Biosciences

Please note: The information displayed on this page might be outdated.
Maxwell Biosciences: Developer of a novel synthetic biomimic drug class intended to target human virus. The company's virucidal drugs mimic natural antimicrobial peptides and destroy a broad range of viruses directly, irreversibly and permanently inactivating the virus itself. Maxwell drug candidates have direct virucidal action against SARS-CoV-2, the COVID-19 virus. Maxwell's drugs have undergone testing and is effective against Herpes Simplex Virus-1 (HSV-1), Chikungunya, Hepatitis B Virus (HBV ), and Influenza.
Based in...
US - West South Central
Austin, TX
United States

Company Participants at Spring Private Company Showcase

Joshua McClure
Maxwell Biosciences, CEO
A graduate of the USAF Academy, Joshua has over 18 years of experience as a tech company CEO. He is a multi-patent holder with a background in military and commercial intelligence. His knowledge of leadership principles alongside his 2016 big data study of immune proteins’ impact on health outcomes are the foundation of the company.

Upcoming Company Event Participation